P3.12-15 68 Ga DOTA PET/CT in Staging of Broncho-Pulmonary Carcinoid Tumors. Is there a Real Benefit?

Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.

UNLABELLED Detection of epidermal growth factor receptor (EGFR) overexpression in many carcinomas provides important diagnostic information, which can influence patient management. The use of PET may enable such detection in vivo by a noninvasive procedure with high sensitivity. The aim of this study was to develop a method for preparation of a positron-emitting tracer based on a natural ligand...

PETCT in lung cancer staging

Bronchoplasty for primary broncho-pulmonary tumors.

BACKGROUND Parenchyma-sparing procedures are widely used in patients with low-grade malignancies of the airway when anatomically suited lesions exist. This study was conducted to evaluate the short-term and the long-term results of bronchoplastic procedures for patients with centrally located primary bronchopulmonary tumors. METHODS Between 2000 and 2009, 36 patients with primary lung tumors ...

Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience

Introduction: Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, majority of which express somatostatin (SST) receptors. Recently, with the widespread use of positron emission tomography/computed tomography (PET/CT) and development of novel PET tracers like Ga-68 DOTA peptide which specifically bind to somatostatin receptors (SSTR), Ga-68 DOTA peptide PET/CT is used in manageme...

(68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.

BACKGROUND Increased somatostatin receptor (SSTR) expression in patients with undifferentiated nasopharyngeal carcinoma (NPC) has been demonstrated with receptor autoradiography, (111) In-Octreotide scintigraphy, and (68) Ga-DOTA-TOC positron emission tomography (PET)/CT imaging. We sought to compare and correlate the uptake of fluorodeoxyglucose (FDG) and DOTA-NOC in undifferentiated NPC to as...